SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)

07-Feb-2007

SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary siRNA (AtuRNAi) technology and modifies the Expression or function of one specific gene target, which is involved in the progression of Age-related Macular Degeneration (AMD). RTP-801i has been licensed to Quark Biotech for the treatment of AMD and other diseases. This Phase I study is being funded by Pfizer Inc., which in-licensed RTP-801i for the treatment of AMD.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances